Novartis AG (NOVN) Given a CHF 78 Price Target at UBS AG
Novartis AG (VTX:NOVN) has been given a CHF 78 price objective by analysts at UBS AG in a research report issued on Monday, www.boersen-zeitung.de reports. The brokerage presently has a “neutral” rating on the stock.
A number of other research firms also recently issued reports on NOVN. Morgan Stanley set a CHF 88 price target on Novartis AG and gave the company a “buy” rating in a research note on Wednesday, July 26th. Jefferies Group LLC set a CHF 97 price target on Novartis AG and gave the company a “buy” rating in a research note on Monday, July 24th. Goldman Sachs Group, Inc. (The) set a CHF 80 price target on Novartis AG and gave the company a “neutral” rating in a research note on Thursday, July 20th. Societe Generale set a CHF 91 price target on Novartis AG and gave the company a “buy” rating in a research note on Wednesday, July 19th. Finally, Deutsche Bank AG set a CHF 81 price target on Novartis AG and gave the company a “neutral” rating in a research note on Wednesday, July 19th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company. Novartis AG currently has a consensus rating of “Hold” and a consensus price target of CHF 85.37.
Novartis AG (VTX NOVN) traded up 0.95% during mid-day trading on Monday, reaching CHK 85.25. The company had a trading volume of 3,131,662 shares. The stock has a 50 day moving average price of CHK 82.94 and a 200 day moving average price of CHK 79.99. The company has a market capitalization of CHK 199.73 billion and a P/E ratio of 31.12. Novartis AG has a one year low of CHK 67.40 and a one year high of CHK 85.40.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/23/novartis-ag-novn-given-a-chf-78-price-target-at-ubs-ag.html.
About Novartis AG
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.